Demand for Vascular Closure Devices in USA (2025 - 2035)

Demand for Vascular Closure Devices in USA 2025 to 2035

The USA vascular closure devices demand is valued at USD 591.4 million in 2025 and is projected to reach USD 812.7 million by 2035, reflecting a CAGR of 3.2%. Growth is supported by increased catheter-based cardiovascular and peripheral interventions where rapid hemostasis and early ambulation improve patient outcomes. Higher procedural volumes in older populations continue to strengthen demand across interventional cardiology and radiology settings.

Quick Stats for USA Vascular Closure Devices Demand

• USA Vascular Closure Devices Sales Value (2025): USD 591.4 million
• USA Vascular Closure Devices Forecast Value (2035): USD 812.7 million
• USA Vascular Closure Devices Forecast CAGR (2025 to 2035): 3.2%
• Leading Product in USA Vascular Closure Devices Demand: Femoral Access Devices
• Key Growth Regions in USA Vascular Closure Devices Demand: West USA, South USA, Northeast USA
• Top Players in USA Vascular Closure Devices Demand: Abbott Laboratories, Terumo Corporation, Medtronic Plc, Teleflex Incorporated, Johnson & Johnson

What is the Growth Forecast for Vascular Closure Devices Industry in USA through 2035?

The West, South, and Northeast regions show strong adoption driven by large hospital networks and advanced cardiac care infrastructure. Key suppliers include Abbott Laboratories, Terumo Corporation, Medtronic Plc, Teleflex Incorporated, and Johnson & Johnson. Their strategies focus on improved sealant materials, next-generation deployment mechanisms, and product portfolios tailored for both femoral and emerging radial access requirements to support evolving interventional practice standards.

Demand for vascular closure devices in the United States remains in an expansion phase, yet certain indicators show movement toward a gradual saturation point. High adoption across cardiac catheterization labs, interventional radiology units, and peripheral vascular centers has already replaced manual compression in many procedures. Growth continues as procedure volumes rise due to aging demographics and greater use of minimally invasive interventions. Most large hospitals already use closure devices as a standard practice, which limits new site expansion.

Incremental gains now rely on product upgrades such as faster hemostasis, improved biocompatibility, and reduced post-procedure complications. Ambulatory surgical centers add ongoing but slower contribution. Competitive pricing pressure and purchasing consolidation reduce the pace of uptake across mature facilities. Awareness among clinicians is high, meaning expansion is not driven by education gaps. Future gains depend on next-generation technologies that demonstrate clear clinical advantage in complex cases. The sector is advancing but trending toward moderate saturation because core demand from major cardiovascular service providers is already met.

USA Vascular Closure Devices Key Takeaways

Metric	Value
USA Vascular Closure Devices Sales Value (2025)	USD 591.4 million
USA Vascular Closure Devices Forecast Value (2035)	USD 812.7 million
USA Vascular Closure Devices Forecast CAGR (2025-2035)	3.2%

Why is the Demand for Vascular Closure Devices in the USA Growing?

Demand for vascular closure devices in the USA is increasing because hospitals and surgical centers perform a high volume of interventional cardiology and radiology procedures such as angioplasty, stent placement and endovascular repairs. After using large-bore catheters, clinicians rely on closure devices to seal the access site quickly and minimize bleeding or vascular complications. Use of these devices reduces recovery time and allows faster patient mobilization, which supports same-day discharge protocols and more efficient patient throughput. Expansion of outpatient surgical and catheterization suites drives adoption because closure devices help standardize post-procedure care while reducing demands on nursing staff. Aging demographics and rising cardiovascular disease prevalence contribute to procedural growth and recurring demand for closure solutions.

Manufacturers provide a variety of closure mechanisms, including plug-based, suture-based and collagen-based systems, to suit different clinical scenarios and patient anatomies. Devices with proven safety records gain wider acceptance among clinicians seeking reliable outcomes and lower complication rates. Constraints include device cost and requirement for clinician training to ensure proper deployment. Some vascular access sites remain unsuitable for certain closure systems, which may limit use. Hospitals may evaluate cost per procedure before replacing manual compression when volumes are modest.

Which Product Types and Procedures Lead Demand for Vascular Closure Devices in the United States?

Demand for vascular closure devices in the United States reflects consistent use of minimally invasive cardiovascular procedures where rapid hemostasis and early ambulation are required. Clinical decision factors include access route, vessel diameter, patient bleeding risk, and interventional workflow efficiency. Increased adoption follows a shift toward catheter-based therapies across cardiology and vascular care networks. Growth benefits from quality-of-care mandates that reduce post-procedure complications and recovery duration.

By Product, Femoral Access Devices Hold the Largest Share

Femoral access closure devices account for 40.0%. Large-bore access remains common in diagnostic angiography and interventional cardiology. These devices support secure vessel sealing that minimizes hospital stay. Active closure devices represent 25.0%. Suture-based and clip-based systems support predictable performance in complex accesses. Passive devices contribute 20.0%. Collagen-based plugs serve lower-risk cases where simplified handling and broad anatomical readiness are prioritized. Radial closure devices hold 15.0%. Use aligns with clinical preference for reduced bleeding and enhanced patient mobility in radial-access interventions. Adoption patterns reflect clinician familiarity, post-procedure discharge goals, and reduction of access-site complications.

Key Points:

• Femoral access devices dominate due to large-bore procedure prevalence
• Active solutions strengthen closure reliability in interventional workflows
• Radial products align with mobility-focused care strategies

By Procedure, Coronary Angiograms Account for the Largest Share

Coronary angiography represents 30.0%. High diagnostic volume drives frequent vascular access closures in hospitals. Percutaneous coronary intervention holds 28.0%. Increased stent placement rates support closure utilization among cardiovascular patients requiring efficient discharge targets. Endovascular aneurysm repair contributes 14.0%, and transcatheter aortic valve implantation accounts for 10.0%. Large bore vascular access procedures collectively represent 10.0%, requiring closure systems engineered for enhanced mechanical integrity. Percutaneous LV assist device placement contributes 8.0%, where hemostasis performance influences device removal outcomes. Procedure mix reflects advanced structural heart therapy expansion paired with strong safety emphasis.

Key Points:

• Coronary diagnostic and stent procedures heavily influence volume
• Structural heart therapies contribute to large-bore product usage
• Efficiency gains link directly with post-procedure mobility and discharge timing

What are the Key Dynamics in the Vascular Closure Devices Industry?

Growth of minimally invasive cardiovascular procedures, rising focus on early ambulation and increased adoption in outpatient settings drive demand.

In the United States, vascular closure devices support hemostasis after catheter-based interventions performed in cardiology and interventional radiology labs. Hospitals and ambulatory surgery centers increase reliance on percutaneous coronary intervention, electrophysiology studies and peripheral angioplasty, which creates a continuous need for rapid and reliable femoral artery closure. Clinicians seek products that reduce manual compression time and shorten bedrest requirements for patients recovering from diagnostic and therapeutic catheter procedures.

Payers and providers align around value-based care models that prioritize shorter recovery periods, lower complication rates and faster discharge. Ambulatory facilities add closure devices to enable same-day procedures with predictable throughput and efficient room turnover. These clinical and operational priorities maintain steady procurement across USA institutions performing high volumes of vascular access procedures.

Pricing pressure, anatomical access shifts and standardized purchasing controls restrain growth.

Cost evaluation for single-use closure devices influences selection in facilities where budgets remain tight. Adoption may slow when clinicians transition coronary access to the radial artery, reducing femoral punctures in certain procedural categories. Purchasing committees enforce product standardization policies that limit brand variety and extend vendor review cycles across multi-campus systems. Training requirements influence usage in centers with nursing turnover or limited device education time. Low-acuity diagnostic cases with minimal bleeding risk sometimes continue using manual compression, reducing device demand in selected populations. These considerations limit accelerated expansion across all care environments.

Shift toward extravascular technologies, increased use in structural heart interventions and rising integration with radial-to-femoral hybrid workflows define key trends.

Manufacturers advance closure products that avoid intravascular components to support simplified deployment and reduce imaging needs. Structural heart programs adopt reliable closure devices during large-bore femoral access used for transcatheter valve therapies and endovascular aortic procedures. Workflow planning aligns closure decisions with recovery pathways that target walking readiness within hours of the procedure.

Device design emphasizes smaller profiles and tactile feedback to improve handling consistency among diverse operator skill levels. Postmarket analytics track bleeding events and recovery metrics to refine purchasing strategies in high-volume centers. These developments indicate durable, procedure-driven demand for vascular closure devices across the United States supported by efficiency goals, outpatient care growth and ongoing cardiovascular innovation.

Analysis of the Demand for Vascular Closure Devices in the USA by Region

Demand for vascular closure devices in the United States grows as hospitals and outpatient cardiovascular centers seek efficient hemostasis solutions after catheter-based diagnostic and interventional procedures. Healthcare systems prioritize workflow efficiency, mobility recovery, and reduced post-procedure complications. Manufacturers supply plug-, suture-, and clip-based devices used in angiography, percutaneous coronary interventions, and electrophysiology cases.

Procurement planning considers patient-volume forecasts and operator learning requirements. West USA retains the fastest expansion at 3.7% CAGR, followed by South USA at 3.3%, Northeast USA at 3.0%, and Midwest USA at 2.6%. Facility administrators examine product-performance consistency, vascular-access compatibility, and supply-chain resilience supporting uninterrupted procedural schedules.

Region	CAGR (2025-2035)
West USA	3.7%
South USA	3.3%
Northeast USA	3.0%
Midwest USA	2.6%

How is the West USA driving demand for vascular closure devices?

West USA posts 3.7% CAGR, supported by high interventional cardiology activity in California and surrounding states. Hospital networks emphasize devices that support rapid patient mobilization to increase room turnover and reduce extended post-procedure monitoring. Physicians evaluate closure reliability in large-bore procedures associated with structural-heart and electrophysiology interventions. Tender evaluations include seal-strength stability in diverse vessel conditions. Inventory coverage extends to ambulatory surgical centers that maintain short-stay recovery pathways. Procurement teams assess compatibility with existing guide-sheath profiles and staff familiarity to reduce variability.

• Strong procedure volumes increasing baseline adoption
• Short-stay recovery strategies influencing device choice
• Physician preferences aligned with sealing performance
• Product compatibility shaping supply selection

How is the South USA shaping demand?

South USA expands at 3.3% CAGR, influenced by extensive cardiovascular disease incidence across Texas and Gulf Coast states. Providers integrate closure devices to support hemostasis during routine catheter-based care in high-volume facilities. Buyers focus on predictable deployment mechanisms that reduce dependence on manual compression during peak caseloads. Hospital administrators include closure-related efficiency metrics when evaluating treatment pathways that support faster discharge readiness. Training access strengthens user confidence among new interventional teams.

• Elevated cardiovascular-care activity maintaining consistent use
• Efficiency goals guiding transition away from manual compression
• Evaluation of discharge timing linked to adoption levels
• Training support improving utilization confidence

How is the Northeast USA influencing usage patterns?

Northeast USA shows 3.0% CAGR, shaped by procedure concentration in academic medical centers and research-driven hospitals in New York, New Jersey, and Massachusetts. Clinicians review closure behavior in complex access sites during high-acuity interventions. Decision-makers prioritize clinically validated deployment systems delivering reliable outcomes with variable patient physiology. Predictable recovery supports bed-management planning in dense urban locations. Pharmacy and procurement teams monitor post-market evidence to confirm performance benchmarks.

• Academic hospitals directing advanced procedural use
• Evaluation of reliability in complex intervention settings
• Strong bed-management requirements affecting product choice
• Evidence-based decision structures shaping device approval

How is the Midwest USA contributing to adoption growth?

Midwest USA maintains 2.6% CAGR, with adoption driven by structured catheter-based care across Illinois, Michigan, and Ohio. Clinicians seek closure devices that maintain workflow predictability in facilities serving mixed-acuity patient populations. Product pricing and supply stability influence purchase decisions where budget planning remains conservative. Adoption expands steadily as staff certification and familiarity improve. Vendors support training linked to procedural-volume growth forecasts across regional cardiovascular centers.

• Mixed-acuity patient settings driving essential use
• Value-focused procurement shaping inventory planning
• Staff capability influencing consistent implementation
• Vendor training aligned with regional care expansion

What is the competitive landscape of demand for vascular closure devices in the United States?

Demand for vascular closure devices in the United States reflects strong adoption in interventional cardiology and peripheral vascular procedures. Hospitals and catheterization labs select products that support quick hemostasis, consistent access site integrity, and shorter patient ambulation times. Procurement teams evaluate device compatibility with common sheath diameters, operator learning requirements, and long-term safety evidence. Reimbursement stability strengthens vendor relationships with large health systems.

Brand familiarity and widely published clinical data support repeat purchasing. Terumo Corporation supplies polymer-based and angiographic solutions used in radial and femoral pathways. USA deployment from established distribution networks maintains visibility among cardiologists and vascular surgeons.

Medtronic plc provides implantable and extravascular closure options designed to reduce reliance on manual compression. Healthcare providers note standardized workflows during high-volume procedures. Teleflex Incorporated offers access site management systems that support predictable seal formation with ease of use for new operators. Johnson & Johnson participates through surgical and interventional subsidiaries where closure capability aligns with broader cardiovascular portfolios.

Competitive positioning depends on clinical performance across varied anatomies, inventory availability for 24-hour intervention units, and training programs for staff proficiency. Institutions track outcomes through internal quality metrics that influence continuing product selection.

Key Players in USA Vascular Closure Devices Demand

• Abbott Laboratories
• Terumo Corporation
• Medtronic Plc
• Teleflex Incorporated
• Johnson & Johnson

Scope of the Report

Items	Values
Quantitative Units	USD million
Product	Femoral Access Devices, Passive Devices, Active Devices, Radial Closure Devices
Procedure	Coronary Angiograms (Angiography), Percutaneous Coronary Intervention (PCI), Endovascular Aneurysm Repair, Transcatheter Aortic Valve Implantation, Percutaneous LV Assisting Devices (pLVAD), Large Bore Vascular Access
End User	Hospitals, Independent Catheterization Labs, Ambulatory Surgical Centers
Regions Covered	West USA, South USA, Northeast USA, Midwest USA
Key Companies Profiled	Abbott Laboratories, Terumo Corporation, Medtronic Plc, Teleflex Incorporated, Johnson & Johnson
Additional Attributes	Dollar sales by product category, procedure type, and end-user segments; regional use influenced by PCI volumes, catheterization lab capacity, and adoption of radial access; competitive landscape with active and passive sealing technologies; growth driven by minimally invasive cardiovascular interventions and reduced time-to-ambulation post-procedure; procurement via hospitals and outpatient cardiac centers.

USA Vascular Closure Devices Demand by Segments

Product:

• Femoral Access Devices
• Passive Devices
• Active Devices
• Radial Closure Devices

Procedure:

• Coronary Angiograms (Angiography)
• Percutaneous Coronary Intervention (PCI)
• Endovascular Aneurysm Repair
• Transcatheter Aortic Valve Implantation
• Percutaneous LV Assisting Devices (pLVAD)
• Large Bore Vascular Access

End User:

• Hospitals
• Independent Catheterization Labs
• Ambulatory Surgical Centers

Region:

• West USA
• South USA
• Northeast USA
• Midwest USA